Date: 2011-07-05
Type of information:
Compound: ReN001
Company: ReNeuron (UK) Angel Biotechnology (UK)
Therapeutic area: Cerebrovascular diseases
Type agreement: manufacturing
production
Action mechanism: stem cell therapy
Disease: stroke
Details: ReNeuron has signed a new contract with Angel Biotechnology for development and GMP (Good Manufacturing Practice) manufacturing services in support of its development programme for its ReN001 stem cell therapy for stroke.
The work programme is expected to continue through to mid-2012 and includes the GMP manufacture and related work for future cohorts of patients in ReNeuron\'s ongoing PISCES clinical trial with ReN001 in stroke. The contract is structured in such a way that it allows much more flexibility for both parties in terms of work scheduling, thereby giving ReNeuron the ability to match the needs and opportunities of its growing development programmes in real time.
Financial terms:
Latest news:
